Corporate Banner
Satellite Banner
Technology Networks Header
Thursday, October 23, 2014
 
Register | Sign in
Home Page > Videos > Tumour Regression after Intravenous Administration of Novel Tumour-targeted Nanomedicines
  Videos

Return

Tumour Regression after Intravenous Administration of Novel Tumour-targeted Nanomedicines
SELECTBIO

The possibility of using genes as medicines to treat cancer is limited by the lack of safe and efficacious delivery systems able to deliver therapeutic genes selectively to tumours by intravenous administration, without secondary effects to healthy tissues. In order to remediate to this problem, we investigated if the conjugation of the polypropylenimine dendrimer to transferrin, whose receptors are overexpressed on numerous cancers, could result in a selective gene delivery to tumours after intravenous administration, leading to an increased therapeutic efficacy. The objectives of this study are to evaluate the targeting and therapeutic efficacies of a novel transferrin-bearing polypropylenimine dendrimer. The intravenous administration of transferrin-bearing polypropylenimine polyplex resulted in gene expression mainly in the tumours. Consequently, the intravenous administration of the delivery system complexed to a therapeutic DNA encoding TNF led to a rapid and sustained tumour regression over one month (90% complete response, 10% partial response on A431 human epidermoid tumours). It also resulted in tumour suppression for 60% of PC-3 and 50% of DU145 prostate tumours. The treatment was well tolerated by the animals, with no apparent signs of toxicity. Transferrin-bearing polypropylenimine is therefore a highly promising delivery system for cancer therapy

Request more information
Company product page



For access to this article, enter your email address to instantly recieve a Password Reset link.

Please enter your email address below:

Existing users please Sign In here. Don't have an account? Register Here for free access.

Don't have an account? | Register Here

Scientific News
NIH Begins Early Human Clinical Trial of VSV Ebola Vaccine
Human testing of a second investigational Ebola vaccine candidate is under way at the National Institutes of Health’s Clinical Center in Bethesda, Maryland.
Silencing the FOXP2 Speech Gene Causes Breast Cancer Cells to Metastasize
BIDMC investigators make the surprising discovery that a gene associated with speech and language is linked to advanced breast cancer.
Magnesium Cuts Diabetes Risk
Only about half of Americans get the recommended daily amount in their diet.
Major Step Forward in Understanding of Viruses
Scientists unlock exact structure of Hepatitis A virus.
TGAC Leads Research To Help Identify Animal-To-Human Transmitted Diseases
The Genome Analysis Centre (TGAC) will lead research into the development of bioinformatics to support the identification and characterisation of viruses through metagenomics.
Lab-developed Intestinal Organoids form Mature Human Tissue in Mice
Study produces unprecedented model to study intestinal diseases.
Study Investigates Inherent Contamination in Deep Well Microplates
Study gives data on microplates from numerous manufacturers based in Europe, USA and China.
Revalesio’s Drug Shows Promise in Treating Alzheimer’s
Multiple published research studies outline the potential for RNS60 to effectively treat Alzheimer’s disease by protecting neuronal function and restoring neuronal plasticity.
Shaking Up Cell Biology
Researchers focus in on decades old mystery.
Drinking Water Odors, Chemicals Above Health Standards Caused by 'Green Building' Plumbing
Several types of plastic pipes in eco-friendly green buildings in the United States have been found to leach chemicals into drinking water that can cause odors and sometimes exist at levels that may exceed health standards.
Scroll Up
Scroll Down
Skyscraper Banner
Skyscraper Banner
Follow TechNetcom1 on Twitter
Technology Networks Ltd. on LinkedIn
Go to LabTube.tv